Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05320198 · ClinicalTrials.gov registry record · Phase 1

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

A Phase 1 study of Myelodysplastic Syndromes and Anemia, sponsored by Disc Medicine.

Recruiting
Registry status
Phase 1
Development phase
150
Enrollment target
20
Study locations

NCT05320198 is a Phase 1 study of Myelodysplastic Syndromes and Anemia that is actively recruiting participants, run by Disc Medicine. The registered enrollment target is 150 participants, below the 284-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05320198, a Phase 1 study of Myelodysplastic Syndromes and Anemia, is actively recruiting participants, sponsored by Disc Medicine.

RECRUITING
Registry status
Phase 1
Development phase
150 participants
Enrollment target
20
Study locations

Study Summary

This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.

Conditions Studied

Myelodysplastic Syndromes Anemia Myelofibrosis Primary Myelofibrosis Post-Essential Thrombocythemia Myelofibrosis Myelofibrosis; Anemia Myelofibrosis Due to and Following Polycythemia Vera

Interventions

  • DRUG DISC-0974

Study Locations (20)

Florida

  • Mayo Clinic Jacksonville - Jacksonville
  • Sylvester Cancer Center - U Miami - Miami
  • Moffitt Cancer Center - Tampa

Ohio

  • Gabrail Cancer Center Research - Canton
  • Cleveland Clinic - Cleveland
  • The Ohio State University - Columbus

California

  • City of Hope - Duarte - Duarte
  • City of Hope - Lennar - Irvine

New York

  • Memorial Sloan Kettering Cancer Center - New York
  • Icahn School of Medicine at Mount Sinai - New York

Pennsylvania

  • Sargon Research - Pennsylvania Cancer Specialists and Research Center - Gettysburg
  • University of Pennsylvania - Philadelphia

Colorado

  • University of Colorado Anschutz Medical Campus - Aurora

Georgia

  • Emory Winship Cancer Institute - Atlanta

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2022-06-06
Est. Completion 2026-09
Phase Phase 1

Sponsor

Disc Medicine

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05320198

The ClinicalTrials.gov registry entry for NCT05320198 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (47% lower). The listed sponsor is Disc Medicine, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 1 intervention - of which DISC-0974 is the first listed.

NCT05320198 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Ohio, California.

Frequently Asked Questions

What is clinical trial NCT05320198 about?

NCT05320198 is a clinical study titled "Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia". This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.

What is the current status of trial NCT05320198?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2022-06-06. Estimated completion is 2026-09.

What conditions does trial NCT05320198 study?

This clinical trial studies the following conditions: Myelodysplastic Syndromes, Anemia, Myelofibrosis, Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis.

What interventions are being tested in trial NCT05320198?

The interventions under investigation include: DISC-0974 (DRUG).

Who is sponsoring clinical trial NCT05320198?

This trial is sponsored by Disc Medicine, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05320198 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myelodysplastic Syndromes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Myelodysplastic Syndromes

All registered trials for this condition

Anemia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.